IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Strong balance sheet of $393.9 million cash, cash equivalents and marketable securities as of September 30, 2022 is anticipated to fund planned operations into...

Related Keywords

Sydney ,New South Wales ,Australia ,Russia ,Ukraine ,Yujiros Hata ,Werner Helicase ,Amgen ,Vincent Hospital Sydney ,Nasdaq ,Biosciences Inc ,Pfizer ,Exchange Commission ,Wrn Rd Services ,Program Updates ,First In Human Phase ,Pol Theta Helicase ,Chief Executive Officer ,Crizotinib Combination Therapy ,Metastatic Uveal Melanoma ,Disease Control Rate ,Overall Response Rate ,Tumor Reduction ,Study Follow Up ,Progression Free Survival ,Orphan Drug ,Uveal Melanoma ,Adjuvant Uveal Melanoma ,Investigator Sponsored Trial ,Hospital Sydney Limited ,Clinical Trial Collaboration ,Supply Agreement ,Pol Theta ,Pol Theta Helicase Inhibitor ,Investor Relations ,Investor Rd Day ,Quarterly Report ,Vice President ,Chief Financial Officer ,Ideaya Biosciences ,Nc ,